

1648

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

William Fields
Type or print name

William Fields
Signature

July 14, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
HALLENBECK ET AL.
APPLICATION NO: 09/870,203
FILED: MAY 30, 2001
FOR: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER
PROTEINS

Examiner: Myron Hill
Art Unit: 1648
Confirmation No.: 7861
Atty. Docket: 4-31452A

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Sir:

Enclosed please find the following:

- a. Supplemental Information Disclosure Statement;
- b. PTO Form 1449 with cited references; and
- c. Return postcard.

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
Phone No. (301) 208-2440

Date: July 14, 2003

RECEIVED
JUL 17 2003
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
17 2002

JUL 17 2003
INTER 10

JUL 17 2003
TECH CENTER 1600/2900

IN RE APPLICATION OF Art Unit: 1648
HALLENBECK ET AL. Examiner: Myron Hilt
APPLICATION NO: 09/870,203
FILED: MAY 30, 2001
FOR: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER
PROTEINS

Commissioner for Patents
U.S. Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is submitted in accordance with 37 CFR §1.97(c) and is supplemental to the Information Disclosure Statement filed December 14, 2001. Pursuant to 37 C.F.R. §1.97(e)(1), each item of information contained in this supplemental information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this supplemental information disclosure statement.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

J. Timothy Meigs
J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(301) 258-4715

Date: July 14, 2003

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION



(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31452A
APPLICATION NO.
09/870,203
APPLICANT
HALLENBECK ET AL.
FILING DATE
MAY 30, 2001Group
1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						<i>RECEIVED</i>
AB						<i>JUL 17 2003</i>
AC						<i>TECH CENTER 1600/2900</i>
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	WO 00/15823	3/23/00	WIPO				<input type="checkbox"/>	<input type="checkbox"/>
AN	WO 98/07865	2/26/98	WIPO				<input type="checkbox"/>	<input type="checkbox"/>
AO	WO 98/50053	11/12/98	WIPO				<input type="checkbox"/>	<input type="checkbox"/>
AP							<input type="checkbox"/>	<input type="checkbox"/>
AQ							<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	International Search Report for PCT/EP01/06286, dated July 1, 2003
AS	
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.